BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shim JH, Park J, Choi J, Park BJ, Kim C. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2009;135:617-25. [DOI: 10.1007/s00432-008-0496-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Køstner AH, Sorensen M, Olesen RK, Grønbæk H, Lassen U, Ladekarl M. Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability. ScientificWorldJournal 2013;2013:931972. [PMID: 23431262 DOI: 10.1155/2013/931972] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
2 Lee JH, Chung YH, Kim JA, Shim JH, Lee D, Lee HC, Shin ES, Yoon JH, Kim BI, Bae SH, Koh KC, Park NH. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer. 2013;119:136-142. [PMID: 22736425 DOI: 10.1002/cncr.27705] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
3 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
4 Matsuda Y, Fukumoto M. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 2011;44:183-9. [PMID: 22179180 DOI: 10.1007/s00795-011-0558-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
5 Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K, Iio E, Miyaki T, Nomura T, Sobue S, Sano H, Hasegawa I, Ohno T, Takahashi Y, Orito E, Joh T. Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma. Cancer Manag Res 2012;4:423-9. [PMID: 23293537 DOI: 10.2147/CMAR.S38684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
6 Welker MW, Lubomierski N, Gog C, Herrmann E, Engels K, Vogl TJ, Bechstein WO, Zeuzem S, Trojan J. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. J Chemother 2010;22:205-11. [PMID: 20566428 DOI: 10.1179/joc.2010.22.3.205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
7 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z, Lou M, Lv J. Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med. 2012;3:171-180. [PMID: 22969864 DOI: 10.3892/etm.2011.398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
8 Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. J Hepatol. 2019;70:684-691. [PMID: 30529387 DOI: 10.1016/j.jhep.2018.11.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 12.8] [Reference Citation Analysis]
9 Lee S, Kim BK, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH. Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. J Hepatocell Carcinoma 2015;2:39-47. [PMID: 27508193 DOI: 10.2147/JHC.S79353] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
10 McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer 2018;105:1-9. [PMID: 30384012 DOI: 10.1016/j.ejca.2018.09.031] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
11 Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681-8. [PMID: 23463401 DOI: 10.1007/s00535-013-0770-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
12 Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:123-133. [PMID: 22212946 DOI: 10.1159/000333275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
13 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
14 Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269:603-611. [PMID: 23864102 DOI: 10.1148/radiol.13130150] [Cited by in Crossref: 75] [Cited by in F6Publishing: 88] [Article Influence: 8.3] [Reference Citation Analysis]
15 Kim HY, Park J. Molecularly Targeted Therapies for Hepatocellular Carcinoma: Sorafenib as a Stepping Stone. Dig Dis 2011;29:303-9. [DOI: 10.1159/000327563] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
16 Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer 2013;2:93-107. [PMID: 24159601 DOI: 10.1159/000343845] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
17 Kim HY, Park J, Joo J, Kim H, Woo SM, Lee WJ, Kim C. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma: Outcome of sorafenib therapy in cirrhosis. J Gastroenterol Hepatol 2013;28:1756-61. [DOI: 10.1111/jgh.12310] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
18 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
19 Na W, Ma B, Shi S, Chen Y, Zhang H, Zhan Y, An H. Procyanidin B1, a novel and specific inhibitor of Kv10.1 channel, suppresses the evolution of hepatoma. Biochem Pharmacol 2020;178:114089. [PMID: 32533968 DOI: 10.1016/j.bcp.2020.114089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Kim Y, Park J, Kwak H, Kim BH, Lee JH, Lee IJ, Kim TH, Kim SH, Koh YH, Kim HB, Kim C. Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma. Liver Int 2014;34:1278-86. [DOI: 10.1111/liv.12535] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
21 Dietrich J, Hulme C, Hurley LH. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. Bioorg Med Chem 2010;18:5738-48. [PMID: 20621496 DOI: 10.1016/j.bmc.2010.05.063] [Cited by in Crossref: 95] [Cited by in F6Publishing: 85] [Article Influence: 7.9] [Reference Citation Analysis]
22 Chen D, Zhao P, Li SQ, Xiao WK, Yin XY, Peng BG, Liang LJ. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib. Eur J Surg Oncol. 2013;39:974-980. [PMID: 23845703 DOI: 10.1016/j.ejso.2013.06.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
23 Kim JE, Ryoo B, Ryu M, Chang H, Suh DJ, Lee HC, Lim Y, Kim KM, Kang Y. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 2011;68:1285-90. [DOI: 10.1007/s00280-011-1616-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
24 Kwak H, Park J, Nam B, Yu A, Woo SM, Kim TH, Kim SH, Koh YH, Kim HB, Park SJ, Lee WJ, Hong EK, Kim C. Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area: Outcomes and changes of the HCC cohort. J Gastroenterol Hepatol 2014;29:820-9. [DOI: 10.1111/jgh.12470] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
25 Ying ZL, Li XJ, Dang H, Wang F, Xu XY. Saikosaponin-d affects the differentiation, maturation and function of monocyte-derived dendritic cells. Exp Ther Med. 2014;7:1354-1358. [PMID: 24940438 DOI: 10.3892/etm] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
26 Lim S, Han J, Kim GM, Han KH, Choi HJ. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. J Gastroenterol Hepatol 2015;30:1024-31. [PMID: 25611175 DOI: 10.1111/jgh.12898] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
27 Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Han DH, Kim BK. Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. J Hepatocell Carcinoma 2020;7:403-12. [PMID: 33365287 DOI: 10.2147/JHC.S276528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lo CH, Huang WY, Lee MS, Lin KT, Lin TP, Chang PY, Fan CY, Jen YM. Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma patients who failed or were unsuitable for transarterial chemoembolization. Eur J Gastroenterol Hepatol. 2014;26:345-352. [PMID: 24384685 DOI: 10.1097/meg.0000000000000032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
29 Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, Woo SM, Nam BH. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol. 2012;56:1336-1342. [PMID: 22314421 DOI: 10.1016/j.jhep.2012.01.006] [Cited by in Crossref: 101] [Cited by in F6Publishing: 111] [Article Influence: 10.1] [Reference Citation Analysis]
30 Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology 2021. [PMID: 34918361 DOI: 10.1002/hep.32241] [Reference Citation Analysis]
31 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 183] [Article Influence: 15.2] [Reference Citation Analysis]
32 Peng Z, Chen S, Wei M, Lin M, Jiang C, Mei J, Li B, Wang Y, Li J, Xie X, Chen M, Qian G, Kuang M. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. Radiology. 2018;287:705-714. [PMID: 29390197 DOI: 10.1148/radiol.2018171541] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
33 Tseng HC, Xiong W, Badeti S, Yang Y, Ma M, Liu T, Ramos CA, Dotti G, Fritzky L, Jiang JG, Yi Q, Guarrera J, Zong WX, Liu C, Liu D. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun 2020;11:4810. [PMID: 32968061 DOI: 10.1038/s41467-020-18444-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
34 Song T, Zhang W, Wu Q, Kong D, Ma W. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol Hepatol. 2011;23:1233-1238. [PMID: 21941188 DOI: 10.1097/meg.0b013e32834bd2d0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
35 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
36 Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P, Xia F, Bi F, Li Q. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int 2015;35:2147-54. [PMID: 25676812 DOI: 10.1111/liv.12805] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
37 Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20): 2245-2263 [PMID: 26380650 DOI: 10.4254/wjh.v7.i20.2245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
38 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys. 2012;63:159-169. [PMID: 22477032 DOI: 10.1007/s12013-012-9353-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
39 Sommer CM, Stampfl U, Kauczor HU, Pereira PL. [National S3 guidelines on hepatocellular carcinoma]. Radiologe 2014;54:642-53. [PMID: 25047521 DOI: 10.1007/s00117-014-2656-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
40 Kim HY, Park JW, Nam BH, Kim HK, Choi JI, Kim TH, Kim HB, Kim CM. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol. 2011;26:1612-1618. [PMID: 21517968 DOI: 10.1111/j.1440-1746.2011.06751.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
41 Liu C, Xing W, Si T, Yu H, Guo Z. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. Oncotarget 2017;8:100734-45. [PMID: 29246017 DOI: 10.18632/oncotarget.20140] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
42 Kudo M, Han KH, Kokudo N, Cheng AL, Choi BI, Furuse J, Izumi N, Park JW, Poon RT, Sakamoto M. Liver Cancer Working Group report. Jpn J Clin Oncol. 2010;40 Suppl 1:i19-i27. [PMID: 20870915 DOI: 10.1093/jjco/hyq123] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]